Lv11
50 积分 2024-04-01 加入
Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer
4小时前
已完结
O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
1个月前
已关闭
Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
1个月前
已完结
Consistency and inconsistency in network meta‐analysis: model estimation using multivariate meta‐regression
1个月前
已关闭
Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis
1个月前
已完结
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
1个月前
已完结
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
1个月前
已完结
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
3个月前
已完结
Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)
8个月前
已关闭
皖公网安备34019202002308
